Abstract: The present description relates to methods for clinically assessing Parkinson's disease in a subject using protein biomarkers of erythrocyte-derived extracellular vesicles (EEV).

Abstract: The present description relates to methods for clinically assessing Parkinson's disease in a subject using protein biomarkers of erythrocyte-derived extracellular vesicles (EEV).

Abstract: The present description relates to methods for clinically assessing Parkinson's disease in a subject using erythrocyte-derived extracellular vesicles (EEV) as a biomarker.

Abstract: The present description relates to methods for clinically assessing Parkinson's disease in a subject using protein biomarkers of erythrocyte-derived extracellular vesicles (EEV).

Abstract: The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A2-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components.

Abstract: The present description relates to methods for clinically assessing Parkinson's disease in a subject using erythrocyte-derived extracellular vesicles (EEV) as a biomarker.

Abstract: The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A2-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components.

Abstract: The present invention relates to the use of protein expression profiles of sPLA2 isoforms with clinical relevance to osteoarthritis (OA). In particular, the invention provides methods for diagnosing OA or determining risk factors for development of OA based on expression of sPLA2-IIA.

Abstract: The present invention relates to the use of protein expression profiles of sPLA2 isoforms with clinical relevance to osteoarthritis (OA). In particular, the invention provides methods for diagnosing OA or determining risk factors for development of OA based on expression of sPLA2-IIA.

Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.